Table 2 Summary of drug-related treatment-emergent adverse events
Tacrolimus + MTX (n = 34) | TNFi + MTX (n = 84) | P-value | |
|---|---|---|---|
TEAE, n (%) | 16 (47.1) | 19 (22.6) | 0.0085 |
Adverse drug reaction, n (%) | 7 (20.6) | 6 (7.1) | 0.0501 |
Infections and infestations | 1 (2.9) | 4 (4.8) | |
Upper respiratory tract infection | 0 | 3 (2.5) | |
Disseminated tuberculosis | 1 (2.9) | 0 | |
Oral herpes simplex infection | 0 | 1 (1.19) | |
Gastrointestinal disorders | 4 (11.76) | 0 | |
Abdominal pain | 4 (11.76) | 0 | |
Musculoskeletal disorders | 1 (2.9) | 1 (1.2) | |
Lymphatic system disorders | 0 | 1 (1.19) | |
Lymphadenopathy | 0 | 1 (1.19) | |
Nervous system disorders | 1 (2.94) | 0 | |
Headache | 1 (2.94) | 0 |